Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
Novavax raised doubts about the feasibility of continuing its business after struggles in rolling out its coronavirus jab although it has enough money to fund operations.
The COVID-19 vaccine maker, which described the situation as "subject to significant uncertainty," also announced plans to cut spending
On Tuesday, the company reported a loss of $182 million in the fourth quarter, after posting weaker sales than expected at $357 million.
Consequently, Novavax shares plummeted 25 percent in extended trading.
Novavax is currently gearing up for a fall vaccination campaign and said it plans to focus on delivering an updated COVID-19 vaccine.
The Maryland-based Novavax was an early frontrunner in the global vaccine race but fell behind after being hit by manufacturing and regulatory delays.
The company faced delays in regulatory submissions for its jab, which was only authorized in the US in July last year.
Before that, it received authorization from the European Union, United Kingdom, Canada, and Australia.
